# OnCo record bempegaldesleukin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bempegaldesleukin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bempegaldesleukin" ;
  schema:name "Bempegaldesleukin"@en ;
  schema:description "Bempegaldesleukin was a re-engineered interleukin-2 meant to be a safer version of a famous old immunotherapy. It added nothing to nivolumab in three phase 3 trials."@en ;
  schema:url <https://onco.cc/drugs/bempegaldesleukin/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bempegaldesleukin> ;
  owl:sameAs <http://www.wikidata.org/entity/Q68010523> ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.23.00172> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:phase-2-mirage" ;
  onco:modality "Engineered cytokine (PEGylated IL-2)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/urothelial/> ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:companies <https://onco.cc/companies/bms/>, <https://onco.cc/companies/nektar-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct03635983/>, <https://onco.cc/trials/nct04410445/>, <https://onco.cc/trials/nct03729245/> .